

Division of Hematology/Oncology

DIVISION PROFILE	
Number of Faculty	30
Number of Joint Appointment Faculty	4
Number of Fellows	
Clinical Fellows	8
Number of Graduate Students	1
Number of Support Personnel	355
Annual Total Grant Support (direct)	\$3,685,481
Annual Total Industry Contracts (direct)	\$63,546
Number of Peer Reviewed Publications	53
Patient Encounters	
Outpatient	15,871
Inpatient	13,171

FACULTY LISTING

Franklin O. Smith, MD, Marjory J. Johnson Endowed Chair and Professor of Pediatrics, Director, Division of Hematology/Oncology

Michael Absalon, MD, PhD, Assistant Professor of Clinical Pediatrics

Denise Adams, MD, Associate Professor of Clinical Pediatrics, Oncology Medical Director, Division of Hematology/Oncology; Medical Director, Comprehensive Hemangiomas and Vascular Malformation Clinic

Vinod Balasa, MB BS, Assistant Professor of Clinical Pediatrics, Director, Thrombophilia Program

Jacob Blessing, MD, PhD, Assistant Professor of Clinical Pediatrics

Karen Burns, MD, Assistant Professor of Clinical Pediatrics

Timothy Cripe, MD, PhD, Associate Professor of Pediatrics, Director, Musculoskeletal Tumor Comprehensive Clinic; Director, Translational Research Trials Office

Stella Davies, MB BS, PhD, Jacob G Schmidlapp Endowed Chair and Professor of Pediatrics, Director, Blood and Marrow Transplant Program, Division of Hematology/Oncology; Director, Leukemia Biology Program, Division of Experimental Hematology

Jorge DiMartino, MD, PhD, Research Assistant Professor of Pediatrics

Alexandra Filipovich, MD, Ralph J Stolle Endowed Chair in Clinical Immunology and Professor of Pediatrics, Director, Immunodeficiency and Histiocytosis Program; Medical Director, Hematology/Oncology Diagnostic Laboratory

James Geller, MD, Assistant Professor of Clinical Pediatrics

Ralph Gruppo, MD, Professor of Clinical Pediatrics, Director, Hemophilia and Thrombosis Center

Matthew Hansen, MD, Assistant Professor of Clinical Pediatrics

Richard Harris, MD, Adjunct Professor of Clinical Pediatrics, Director, Bone Marrow Failure Clinic

Sonata Jodele, MD, Assistant Professor of Clinical Pediatrics, Co-Director, Fellowship Training Program, Division of Hematology/Oncology

Clinton Joiner, MD, PhD, Professor of Pediatrics, Director, Comprehensive Sickle Cell Center

Michael Jordan, MD, Assistant Professor of Pediatrics

Theodosia Kalfa, MD, PhD, Research Instructor of Pediatrics

Karen Kalinyak, MD, Professor of Clinical Pediatrics, Hematology Medical Director, Division of Hematology/Oncology

Patrick Kelly, MD, Research Assistant Professor of Pediatrics

Beatrice Lampkin, MD, Professor Emerita of Pediatrics

Parinda Mehta, MD, Assistant Professor of Clinical Pediatrics, Co-Director, Fellowship Program, Division of Hematology/Oncology

Joseph Palumbo, MD, Research Assistant Professor of Pediatrics

John Perentesis, MD, Professor of Pediatrics, Director, Oncology Program, Division of Hematology/Oncology

Janos Sumegi, MD, PhD, Professor of Pediatrics

Mary Sutton, MD, Assistant Professor of Pediatrics

Lars Wagner, MD, Associate Professor of Clinical Pediatrics, Chair, Division of Hematology/Oncology
Scientific Review Committee

Brian Weiss, MD, Research Assistant Professor of Pediatrics

Susanne Wells, PhD, Research Assistant Professor of Pediatrics

David Williams, MD, Beatrice C. Lampkin Endowed Chair and Professor of Pediatrics, Associate
Chairman of Translational Research; Director, Division of Experimental Hematology; Director, Fellowship
Program, Division of Hematology/Oncology

FACULTY JOINT APPOINTMENT LISTING

Michael Jordan, MD, Assistant Professor of Pediatrics, Immunobiology

Patrick Kelly, MD, Research Assistant Professor of Pediatrics, Experimental Hematology

Mary Sutton, MD, Assistant Professor of Pediatrics, Neurology

David A. Williams, MD, Beatrice C Lampkin Endowed Chair and Professor of Pediatrics, Experimental
Hematology

STAFF PHYSICIAN LISTING

Amir Mian, MD, Hospitalist, Blood and Marrow Transplant Program

Joseph Crisalli, MD, Hospitalist, Blood and Marrow Transplant Program

OVERVIEW

The Division of Hematology/Oncology has as its mission the provision of superb, state-of-the-art, care for children with cancer, diseases of the blood and disorders of the immune system. This patient and family focused clinical care is provided in a consistent, efficient, cost-effective and evidence-based manner by faculty with expertise in specific disease states. Patients receive care in a clinical research environment that is supportive of innovative basic, clinical and translational investigation. The division is also committed to the education of students and residents and the training of future leaders in Hematology and Oncology.

Clinical care and the infrastructure for clinical and translational research is provided by multi-disciplinary, disease-focused teams in Oncology (John Perentesis MD, Director), Hemophilia (Ralph Gruppo, MD, Director), Thrombophilia (Vinod Balasa, MD, Director), Sickle Cell Disease (Clint Joiner, MD, PhD, Director), Fanconi Anemia (David Williams, MD and Richard Harris, MD, Co-Directors), Bone Marrow Failure (Richard Harris, MD, Director), Blood and Marrow Transplantation (Stella Davies, MB BS, PhD, Director), Immunodeficiency and Histiocytic Disorders (Lisa Filipovich, MD, Director), and in collaboration with the Department of Surgery, Hemangiomas and Vascular Malformations Program (Denise Adams, MD, Medical Director).

The business operations of the division are led by the Hematology/Oncology Business Unit. The Business Unit is comprised of the Division Director (Franklin O. Smith, MD), the Division's Hematology Medical Director (Karen Kalinyak, MD), the Division's Oncology Medical Director (Denise Adams, MD), Oncology Program Director (John Perentesis, MD), Blood and Marrow Transplant Program Director (Stella Davies, MB BS, PhD), the Clinical the Senior Clinical Director for Patient Services (Cindy Williams, MSN, RN, CPNP), and the new Business Director (Susan Laupola, BS, MA). The division and Business Unit are supported by a Business Manager (Stephanie Hoffman, BA), Division Coordinator (Eva Meunier, BS), Clinical Management and Research Support Core Manager (Peggy Kaiser, RN, BSN), Clinical Laboratory Supervisor (Darryl Hake, M.T. (ASCP), Information Systems Project Manager (Ronda Inman, BS, MS) Marketing and Communications Coordinator (Julia Robertson, BA), Family Support Clinical Manager (Polly Partin-Welch, LISW), Financial Analyst (Heather McBryan, BS) and Administrative Supervisor (Deborah Story). The division employs 355 employees who support the division's clinical, research, and teaching mission. Operationally, Dr. Smith is responsible for all clinical activities and David A. Williams, MD, Director of the Division of Experimental Hematology and Associate Chair for Translational Research has responsibility for all research space and laboratory-based research.



Left to Right: (1st row) M. Hansen, P. Kelly, T. Cripe, B. Lampkin, F. Smith, T. Kalfa, D. Adams, P. Mehta (2nd row) K. Kalinyak, S. Jodele, J. DiMartino, K. Burns, R. Harris (3rd row) D. Williams, R. Rucknagel, M. Absalon, B. Weiss, M. Jordan, S. Wells

HIGHLIGHTS

In close collaboration with the Division of Experimental Hematology, the Division of Hematology/Oncology continues to build clinical, translational and clinical research programs that are disease-focused and based upon the scientific themes of stem cell biology, molecular and gene therapy, cell signaling, leukemia biology and cancer biology, including neuro-oncology.

The clinical services are aligned in a disease specific manner with clinical faculty and services in hematology, blood and marrow transplantation and immunodeficiency, and oncology. Under the direction of John Perentesis, MD, the division's Oncology Program Director, clinical and laboratory-based oncology faculty are being recruited to develop programs in leukemia and lymphoma, neuro-oncology, neuroblastoma, sarcomas, liver kidney tumors, long-term follow-up and outcomes, and developmental therapeutics and pharmacogenetics. New faculty recruited into the Oncology Program include: Michael Absalon, MD, PhD (St. Jude Children's Research Hospital) and Karen Burns, MD (University of Wisconsin). Under the Direction of Stella Davies, MB BS, PhD, new faculty recruited into the Blood and Marrow Transplantation Program include: Parinda Mehta, MD (Cincinnati Children's Hospital Medical Center). The division also hired Amir Mian, MD and Joseph Crisalli, MD (Cincinnati Children's Hospital Medical Center) as staff physicians on the Blood and Marrow Transplant Unit. Additional faculty recruitment in the Division of Hematology/Oncology is ongoing.

Clinical services for the division are provided on the fifth floor of the A Building. This includes a 24 bed hematology and oncology inpatient unit, a 14 bed blood and marrow transplant inpatient unit, and a 10 bed Day Hospital. The outpatient unit is contiguous with the inpatient units. The number of physician encounters has more than tripled over the past 5 years. This growth has been associated with a steady improvement in patient satisfaction.

In collaboration with Department of Surgery, dramatic increases in patient referrals have been seen in the Hemangiomas and Vascular Malformation Program led by Dr. Richard Azizkhan (Surgery) and Dr. Denise Adams (Hematology/Oncology).

Additional progress has been made in the growth of the Clinical Management and Research Support Core. This core, under the leadership of Dr. Perentesis and Peggy Kaiser, assists investigators in the conduct of

human clinical trials, assures the appropriate conduct of clinical trials, maximizes safety to research participants, protects the integrity and confidentiality of research data and ensures compliance with local and federal regulations. This office now conducts over 200 research studies involving over 1000 children. Psychological, social and spiritual care to the division's patients is provided by the Family Support Network. Especially noteworthy is the large number of enrollments on phase I studies and in collaboration with the Division of Experimental Hematology and the Translational Research Trials Office ongoing enrollment in 2 gene therapy studies.

The division's fellowship training program has sustained continued growth under the direction of Dr. David Williams with Drs. Sonata Jodele and Parinda Mehta serving as co-directors. Four fellows began training in July 2005 with another four fellows recruited to begin training in July 2006.

The division's academic success is highlighted by national and international leadership by faculty members, the submission of 50 new grants and contracts during the past year, the receipt of 16 new grants and contracts, with 9 grant submissions still pending. In addition, the division faculty published 60 manuscripts, reviews and chapters. Grants and awards were received by faculty and staff in the Division of Hematology from the following institutions and organizations: Cancer Free Kids (4), National Institutes of Health (including subcontracts) (25), Cascade (1), Center for Disease Control (1), Maternal Child Health (1), Rho (1), National Hemophilia Foundation (1), Ohio Department of Health (1), SAMHSA (1), FDA (1), and USIDNET (1).

TRAINING

Francis Eshun, MD	PGY-IV	University of Ghana Medical School
Sabine Mellor-Heineke, MD	PGY-IV	Hanover Medical School
Heather Mittiga, MD	PGY-IV	Case Western University
Philip Roehrs, MD	PGY-IV	University of South Carolina School of Medicine
Deepika Bhatla, MD	PGY-V	University of Kentucky Medical School
Trent Hummel, MD	PGY-V	Children's Hospital of Akron
Eric Mullins, MD	PGY-V	Vanderbilt Medical Center
Reuven Schore, MD	PGY-VI	Schneider Children's Hospital at North Shore University Hospital (Manhasset, NY)

GRANTS, CONTRACTS AND INDUSTRY AGREEMENTS

Grant and Contract Awards	Annual Direct/Project Period	Direct
<hr/>		
Adams, D		
Squamous Cell Carcinoma in Patients with Epidermolysis Bullosa		
Cancer Free Kids	04/01/06 – 03/31/07	\$20,000
<hr/>		
Cripe, T		
Musculoskeletal Tumor Center Tissue Repository		
Cancer Free Kids	04/01/06 – 03/31/07	\$20,000
<hr/>		
Davies, S		
Predictors of Adulthood Leukemia		
National Institutes of Health (University of Minnesota subcontract)		
R01 CA 107143	04/01/05 – 02/28/10	\$10,120/\$56,904
Childhood Cancer Survivor Study		
National Institutes of Health (University of Minnesota subcontract)		
U24 CA 055727	06/01/03 – 08/31/05	\$6,898/\$107,800

Epidemiology of Infant Leukemia			
National Institutes of Health (University of Minnesota subcontract)			
R01 CA 079940	04/01/04 – 03/31/08		\$11,033/\$43,059
Host Factors and Etiology of Leukemia			
National Institutes of Health			
R01 CA 093552	02/01/03 – 11/30/06		\$173,817/\$932,361
Micro RNA Expression in Neuroblastoma			
Cancer Free Kids			
	04/01/06 – 03/31/07		\$20,000
Chairman's Award Children's Oncology Group			
National Institutes of Health (Children's Oncology Group subcontract)			
U10 CA 098543	03/01/05 – 02/28/08		\$11,256/\$33,768
<hr/>			
Filipovich, A			
Hypoxia and Potassium Channel Activity in T-Lymphocytes			
National Institutes of Health (University of Cincinnati subcontract)			
R01 CA 095286	04/01/03 – 03/31/08		\$35,809/\$173,984
<hr/>			
Geller, J			
Developmental Therapy for Metastatic Colorectal Cancer			
National Institutes of Health (St. Jude Children's Research Hospital subcontract)			
R01 CA 108929	05/01/05 – 04/30/08		\$30,140/\$49,750
<hr/>			
Gruppo, R			
Hemophilia Prevention Network			
Centers of Disease Control (Hemophilia Foundation of Michigan subcontract)			
U27 CCU 51382	10/01/97 – 09/29/06		\$22,295/\$134,771
Hemophilia and Thrombosis Center			
Cascade Hemophilia Consortium (Hemophilia Foundation of Michigan subcontract)			
	06/01/03 – 05/31/07		\$49,000/\$124,185
Hemophilia Comprehensive Care			
Maternal and Child Health Bureau (Hemophilia Foundation of Michigan subcontract)			
H30 MC 00015	10/01/97 – 05/31/07		\$17,080/\$126,510
Impact of HIV on Hepatitis C infection in Hemophilia			
National Institutes of Health (University of Pittsburgh subcontract)			
R01 HL 068429	04/01/06 – 03/31/07		\$3,300
Clinical Fellowship Program for Hemophilia-Thrombosis			
National Hemophilia Foundation			
	07/01/05 – 06/30/07		\$90,909/\$181,818
<hr/>			
Joiner, C			
Cincinnati Comprehensive Sickle Cell Center			
National Institutes of Health			
U54 HL 070871	04/01/03 – 03/31/08		\$1,649,060/\$7,906,621
Kalinyak, K	\$208,423	Project 1	
Joiner, C	\$301,385	Project 2	
Joiner, C	\$131,174	Project 3	
Anderson, K	\$207,822	Project 4	
Joiner, C	\$ 94,662	Project 5	
Kalinyak, K	\$335,954	Clinical Core	
Boyd, P	\$141,798	Education/Patient Services	
Joiner, C	\$105,523	Administrative Core	
Joiner, C	\$45,459	C-Data	
Joiner, C	\$72,184	Neuropsych	
Joiner, C	\$4,676	Priapism	
Cincinnati Comprehensive Sickle Cell Center – Supplement			
RHO, Inc			
U54 HL 070871	04/01/03 – 09/30/08		\$22,567/\$74,681

Cincinnati Sickle Cell Project		
Ohio Department of Health		
31-6-006-1-CC	07/01/05 – 06/30/06	\$116,724
The Glycosylation Gap and Diabetic Complications		
National Institutes of Health (University of Cincinnati subcontract)		
R01 DK 063088	09/30/02 – 07/31/06	\$10,835/\$42,825
National Sickle Cell Conference		
National Institutes of Health		
R13 HL 080907	05/15/05 – 04/30/07	\$25,000/\$50,000
<hr/>		
Lampkin, B		
Substance Abuse Conference		
Substance Abuse and Mental Health Services Administration		
H13 TI 017148	08/01/05 – 07/31/06	\$42,043
<hr/>		
Kalinyak, K		
Silent Cerebral Infarct Multi-Center Clinical Trial		
National Institutes of Health (University of Washington subcontract)		
U01 NS 042804	09/30/03 – 06/30/10	\$30,249/\$502,371
<hr/>		
Palumbo, J		
Homeostatic Factors and Tumor Biology		
National Institutes of Health		
K08 HL 074363	07/15/04 – 06/30/08	\$120,750/\$483,000
<hr/>		
Partin-Welch, P		
Independent Community Education/Outreach		
Wyeth Pharmaceuticals		
	02/01/06 – 12/31/06	\$4,548
<hr/>		
Perentesis, J		
Children's Oncology Group Phase I Consortium		
National Institutes of Health (Children's Oncology Group subcontract)		
U01 CA 097542	08/08/02 – 07/31/07	\$20,032/\$207,918
Children's Oncology Group Phase I Consortium (per patient)		
National Institutes of Health (Children's Oncology Group subcontract)		
U01 CA 097542	08/08/02 – 07/31/07	\$20,500/\$100,000
Chairman's Award Children's Oncology Group		
National Institutes of Health (Children's Oncology Group subcontract)		
U10 CA 098543	03/01/03 – 02/28/08	\$31,019/\$136,506
Chairman's Award Children's Oncology Group (per patient)		
National Institutes of Health (Children's Oncology Group subcontract)		
U10 CA 098543	03/01/03 – 02/28/08	\$82,474/\$200,000
Chairman's Award Children's Oncology Group (Phase III)		
National Institutes of Health (Children's Oncology Group subcontract)		
U10 CA 098543	03/01/03 – 02/28/08	\$15,584/\$47,687
Molecular Studies of Down Syndrome Leukemia		
National Institutes of Health		
R01 CA 111778	01/01/05 – 12/31/08	\$160,146/\$652,146
<hr/>		
Smith, F		
Biorad Galactomannan EIA for Diagnosis of Aspergillosis		
National Institutes of Health (Fred Hutchinson Cancer Research Center)		
U01 AI 054736	03/01/04 – 02/28/06	\$26,400/\$34,400
The Children's Oncology Group Award Chairs Grant		
National Childhood Cancer Foundation (Children's Oncology Group subcontract)		
U10 CA 098543	03/01/03 – 02/28/08	\$41,385/\$151,289

Oxandrolone for the Treatment of Marrow Aplasia in Fanconi

Food & Drug Administration

FD R 002612

09/30/05 – 09/29/08

\$99,727/\$320,075

Sumegi, J

The Binding Repertoire of the Duncan's Disease

US Immunodeficiency Network

07/01/05 – 06/30/07

\$99,207/\$199,207

Wagner, L

Assessment of MGMT as a Therapeutic Target for Neuroblastoma

Cancer Free Kids

12/01/05– 11/30/06

\$10,000

New Approaches to Neuroblastoma Therapy Consortium

National Institutes of Health (Children's Hospital of Los Angeles subcontract)

P01 CA 081403

06/01/05– 05/31/10

\$8,333/\$41,665

Children's Oncology Group Phase I Consortium

National Childhood Cancer Foundation (Children's Oncology Group subcontract)

U01 CA 097452

08/01/05– 07/31/07

\$10,000/\$20,000

Gene Transfer to Facilitate Dose-Intensification in the Treatment of Pediatric Brain

Tumors

National Institutes of Health

R21 CA 121578

06/06/06 – 05/31/08

\$142,000/\$284,000

Wells, S

Role and Regulation of the Human DEK Proto-Oncogene

National Institutes of Health

R01 CA 116316

04/01/06 – 02/28/11

\$177,500/\$887,500

Papillomavirus Proteins Mediating Cancer and Senescence

National Institutes of Health

R01 CA 102357

03/01/04 – 02/28/08

\$197,741 /\$810,000

Current Year Direct

\$3,685,481

Industry Contracts

Gruppo, R

Novo Nordisk Pharmaceuticals

\$2,314

Baxter Healthcare Corp.

\$7,611

Rho, Inc.

\$1,501

Joiner, C

Icagen, Inc.

\$2,874

Kelly, P

Novartis

\$5,115

Smith, F

Clinical Trials Office

\$44,131

Current Year Direct Receipts

\$63,546

TOTAL

\$3,749,027

PUBLICATIONS

1. Takagi M, Absalon MJ, McLure KG, Kastan MB. Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin. Cell 2005;123(1):49-63.

2. Adams DM, Lucky AW. Cervicofacial vascular anomalies. I. Hemangiomas and other benign vascular tumors. *Semin Pediatr Surg* 2006;15(2):124-32.
3. Balasa VV. New anticoagulants: a pediatric perspective. *Pediatr Blood Cancer* 2005;45(6):741-52.
4. Bleesing JJ. Sorting out the causes of ALPS. *J Pediatr* 2005;147(5):571-4.
5. Bleesing JJ, Souto-Carneiro MM, Savage WJ, Brown MR, Martinez C, Yavuz S, Brenner S, Siegel RM, Horwitz ME, Lipsky PE, Malech HL, Fleisher TA. Patients with chronic granulomatous disease have a reduced peripheral blood memory B cell compartment. *J Immunol* 2006;176(11):7096-103.
6. Cripe TP, Thomson B, Boat TF, Williams DA. Promoting translational research in academic health centers: navigating the "roadmap". *Acad Med* 2005;80(11):1012-8.
7. Mahller YY, Rangwala F, Ratner N, Cripe TP. Malignant peripheral nerve sheath tumors with high and low Ras-GTP are permissive for oncolytic herpes simplex virus mutants. *Pediatr Blood Cancer* 2006;46(7):745-54.
8. Toretsky JA, Erkizan V, Levenson A, Abaan OD, Parvin JD, Cripe TP, Rice AM, Lee SB, Uren A. Oncoprotein EWS-FLI1 activity is enhanced by RNA helicase A. *Cancer Res* 2006;66(11):5574-81.
9. Davies SM. Hematopoietic stem cell transplantation for immunodeficiencies and genetic diseases. In: Hoffman R, editor. *Hematology : basic principles and practice*; 4th ed. Philadelphia, Pa.: Elsevier Churchill Livingstone; 2005. p. 1703.
10. Davies SM, Radloff GA, DeFor TE, Levran O, Batish SD, Hanenberg H, Auerbach AD. GST genotype may modify clinical phenotype in patients with Fanconi anaemia. *Br J Haematol* 2005;131(1):118-22.
11. Eapen M, Raetz E, Zhang MJ, Muehlenbein C, Devidas M, Abshire T, Billett A, Homans A, Camitta B, Carroll WL, Davies SM. Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. *Blood* 2006;107(12):4961-7.
12. Eapen M, Rubinstein P, Zhang MJ, Camitta BM, Stevens C, Cairo MS, Davies SM, Doyle JJ, Kurtzberg J, Pulsipher MA, Ortega JJ, Scaradavou A, Horowitz MM, Wagner JE. Comparable long-term survival after unrelated and HLA-matched sibling donor hematopoietic stem cell transplantations for acute leukemia in children younger than 18 months. *J Clin Oncol* 2006;24(1):145-51.
13. Geiger H, Schleimer D, Nattamai KJ, Dannenmann SR, Davies SM, Weiss BD. Mutagenic potential of temozolomide in bone marrow cells in vivo. *Blood* 2006;107(7):3010-1.
14. Iannone R, Davies SM. Tissue typing for hematopoietic cell transplantation: newer techniques and newer antigens for which cross-matching is helpful. *Pediatr Transplant* 2005;9 Suppl 7:76-80.
15. Rizzo JD, Wingard JR, Tichelli A, Lee SJ, Van Lint MT, Burns LJ, Davies SM, Ferrara JL, Socie G. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. *Biol Blood Marrow Transplant* 2006;12(2):138-51.
16. Ross JA, Spector LG, Davies SM. Etiology of childhood cancer: recent reports. *Pediatr Blood Cancer* 2005;45(3):239-41.
17. Couriel D, Carpenter PA, Cutler C, Bolanos-Meade J, Treister NS, Gea-Banacloche J, Shaughnessy P, Hymes S, Kim S, Wayne AS, Chien JW, Neumann J, Mitchell S, Syrjala K, Moravec CK, Abramovitz L, Liebermann J, Berger A, Gerber L, Schubert M, Filipovich AH, Weisdorf D, Schubert MM, Shulman H, Schultz K, Mittelman B, Pavletic S, Vogelsang GB, Martin PJ, Lee SJ, Flowers ME. Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. *Biol Blood Marrow Transplant* 2006;12(4):375-96.
18. Filipovich AH. Life-threatening hemophagocytic syndromes: current outcomes with hematopoietic stem cell transplantation. *Pediatr Transplant* 2005;9 Suppl 7:87-91.
19. Filipovich AH, Imashuku S, Henter JI, Sullivan KE. Healing hemophagocytosis. *Clin Immunol* 2005;117(2):121-4.

20. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD, Robinson M, Schubert M, Schultz K, Shulman H, Turner M, Vogelsang G, Flowers ME. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. *Biol Blood Marrow Transplant* 2005;11(12):945-56.
21. Martin PJ, Weisdorf D, Przepiorka D, Hirschfeld S, Farrell A, Rizzo JD, Foley R, Socie G, Carter S, Couriel D, Schultz KR, Flowers ME, Filipovich AH, Saliba R, Vogelsang GB, Pavletic SZ, Lee SJ. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report. *Biol Blood Marrow Transplant* 2006;12(5):491-505.
22. Risma KA, Frayer RW, Filipovich AH, Sumegi J. Aberrant maturation of mutant perforin underlies the clinical diversity of hemophagocytic lymphohistiocytosis. *J Clin Invest* 2006;116(1):182-92.
23. Schultz KR, Miklos DB, Fowler D, Cooke K, Shizuru J, Zorn E, Holler E, Ferrara J, Shulman H, Lee SJ, Martin P, Filipovich AH, Flowers ME, Weisdorf D, Couriel D, Lachenbruch PA, Mittleman B, Vogelsang GB, Pavletic SZ. Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report. *Biol Blood Marrow Transplant* 2006;12(2):126-37.
24. Szigligeti P, Neumeier L, Duke E, Chougnet C, Takimoto K, Lee SM, Filipovich AH, Conforti L. Signalling during hypoxia in human T lymphocytes--critical role of the src protein tyrosine kinase p56Lck in the O2 sensitivity of Kv1.3 channels. *J Physiol* 2006;573(Pt 2):357-70.
25. Kalfa TA, Zimmerman SA, Goodman BK, McDonald MT, Ware RE. Pelger-Huet anomaly in a child with 1q42.3-44 deletion. *Pediatr Blood Cancer* 2006;46(5):645-8.
26. Tarantino MD, Young G, Bertolone SJ, Kalinyak KA, Shafer FE, Kulkarni R, Weber LC, Davis ML, Lynn H, Nugent DJ. Single dose of anti-D immune globulin at 75 microg/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in children. *J Pediatr* 2006;148(4):489-94.
27. Mo J, Lampkin B, Perentesis J, Poole L, Bao L. Translocation (8;18;16)(p11;q21;p13). A new variant of t(8;16)(p11;p13) in acute monoblastic leukemia: case report and review of the literature. *Cancer Genet Cytogenet* 2006;165(1):75-8.
28. Mehta PA, Alonzo TA, Gerbing RB, Elliott JS, Wilke TA, Kennedy RJ, Ross JA, Perentesis JP, Lange BJ, Davies SM. XPD Lys751Gln polymorphism in the etiology and outcome of childhood acute myeloid leukemia: a Children's Oncology Group report. *Blood* 2006;107(1):39-45.
29. Mehta PA, Davies SM. Pre-transplant minimal residual disease in children with acute lymphoblastic leukemia. *Pediatr Blood Cancer* 2006.
30. Widemann BC, Salzer WL, Arceci RJ, Blaney SM, Fox E, End D, Gillespie A, Whitcomb P, Palumbo JS, Pitney A, Jayaprakash N, Zannikos P, Balis FM. Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. *J Clin Oncol* 2006;24(3):507-16.
31. Fraser CJ, Weigel BJ, Perentesis JP, Dusenbery KE, DeFor TE, Baker KS, Verneris MR. Autologous stem cell transplantation for high-risk Ewing's sarcoma and other pediatric solid tumors. *Bone Marrow Transplant* 2006;37(2):175-81.
32. Arceci RJ, Sande J, Lange B, Shannon K, Franklin J, Hutchinson R, Vik TA, Flowers D, Aplenc R, Berger MS, Sherman ML, Smith FO, Bernstein I, Sievers EL. Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia. *Blood* 2005;106(4):1183-8.
33. Radeva JI, VanScoyoc E, Smith FO, Curtis LH, Breitfeld PP. National estimates of the use of hematopoietic stem-cell transplantation in children with cancer in the United States. *Bone Marrow Transplant* 2005;36(5):397-404.
34. Ross JA, Blair CK, Olshan AF, Robison LL, Smith FO, Heerema NA, Roesler M. Periconceptual vitamin use and leukemia risk in children with Down syndrome: a Children's Oncology Group study. *Cancer* 2005;104(2):405-10.

35. Smith FO, Alonzo TA, Gerbing RB, Woods WG, Arceci RJ. Long-term results of children with acute myeloid leukemia: a report of three consecutive Phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891. *Leukemia* 2005;19(12):2054-62.
36. Akbar H, Cancelas J, Williams DA, Zheng J, Zheng Y. Rational design and applications of a Rac GTPase-specific small molecule inhibitor. *Methods Enzymol* 2006;406:554-65.
37. Cancelas JA, Lee AW, Prabhakar R, Stringer KF, Zheng Y, Williams DA. Rac GTPases differentially integrate signals regulating hematopoietic stem cell localization. *Nat Med* 2005;11(8):886-91.
38. Cancelas JA, Williams DA. Stem cell mobilization by beta2-agonists. *Nat Med* 2006;12(3):278-9.
39. Chandra S, Levran O, Jurickova I, Maas C, Kapur R, Schindler D, Henry R, Milton K, Batish SD, Cancelas JA, Hanenberg H, Auerbach AD, Williams DA. A rapid method for retrovirus-mediated identification of complementation groups in Fanconi anemia patients. *Mol Ther* 2005;12(5):976-84.
40. Fulkerson PC, Zhu H, Williams DA, Zimmermann N, Rothenberg ME. CXCL9 inhibits eosinophil responses by a CCR3- and Rac2-dependent mechanism. *Blood* 2005;106(2):436-43.
41. Nassar N, Cancelas J, Zheng J, Williams DA, Zheng Y. Structure-function based design of small molecule inhibitors targeting rho family GTPases. *Curr Top Med Chem* 2006;6(11):1109-16.
42. Schambach A, Bohne J, Chandra S, Will E, Margison GP, Williams DA, Baum C. Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells. *Mol Ther* 2006;13(2):391-400.
43. Schambach A, Galla M, Modlich U, Will E, Chandra S, Reeves L, Colbert M, Williams DA, von Kalle C, Baum C. Lentiviral vectors pseudotyped with murine ecotropic envelope: increased biosafety and convenience in preclinical research. *Exp Hematol* 2006;34(5):588-92.
44. Vlasova IA, McNabb J, Raghavan A, Reilly C, Williams DA, Bohjanen KA, Bohjanen PR. Coordinate stabilization of growth-regulatory transcripts in T cell malignancies. *Genomics* 2005;86(2):159-71.
45. Wang L, Yang L, Filippi MD, Williams DA, Zheng Y. Genetic deletion of Cdc42GAP reveals a role of Cdc42 in erythropoiesis and hematopoietic stem/progenitor cell survival, adhesion, and engraftment. *Blood* 2006;107(1):98-105.
46. Will E, Speidel D, Wang Z, Ghiaur G, Rimek A, Schiedlmeier B, Williams DA, Baum C, Ostertag W, Klump H. HOXB4 inhibits cell growth in a dose-dependent manner and sensitizes cells towards extrinsic cues. *Cell Cycle* 2006;5(1):14-22.
47. Williams DA. FDA guidance document on monitoring delayed adverse events a good first start. *Mol Ther* 2005;12(6):991-2.
48. Williams DA. Gene therapy advances but struggles to interpret safety data in small animal models. *Mol Ther* 2006;13(6):1027-8.
49. Williams DA. An emerging consensus on recommendations to facilitate clinical gene transfer. *Mol Ther* 2006;13(4):637-8.
50. Williams DA. New AAV serotypes may broaden the therapeutic pipeline to human gene therapy. *Mol Ther* 2006;13(1):1-2.
51. Williams DA, Cripe TP. Adventitious mutations in clinical grade vectors: an issue to consider? *Mol Ther* 2006;13(5):831-2.
52. Williams DA, Croop J, Kelly P. Gene therapy in the treatment of Fanconi anemia, a progressive bone marrow failure syndrome. *Curr Opin Mol Ther* 2005;7(5):461-6.
53. Yamada Y, Rothenberg ME, Lee AW, Akei HS, Brandt EB, Williams DA, Cancelas JA. The FIP1L1-PDGFR α fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease. *Blood* 2006;107(10):4071-9.